Using AI to rethink the science of drug development

DeepCure was founded to accelerate breakthrough science, developed by world-leading AI engineers, data scientists and biologists.

Our founding team includes some of the industry’s preeminent drug-discovery scientists and technologists.

Our vision is to use AI-driven discovery to create better molecules and faster cures for every disease-relevant protein target.

Our Investors


Kfir Schreiber

CEO & Co-Founder

Graduate of the MIT Media Lab. Recipient of the inaugural Minsky Fellowship for prominent AI researchers. Previously a Pilot and Major in the Israeli Air Force, with a track record of managing over $100M and 20 people across major R&D projects.

Joseph Jacobson, Ph.D.

CSO & Co-Founder

Associate Professor at the MIT Media Lab. Author of over 70 peer-reviewed papers and conference proceedings. Inventor of 103 issued U.S. patents and a member of the USPTO Investors Hall of Fame. Co-Founder of several successful companies including E-Ink, Gen9, Kovio and IgC Bio.

Thrasyvoulos (Thras) Karydis

CTO & Co-Founder

Graduate of the MIT Media Lab. Deep Learning and AI expert, with years of experience in leading hardware and software projects. Vast experience in establishing and leading collaborations with large pharma companies.

Georg Duenstl, Ph.D​

VP of Drug Discovery

Having served on DeepCure’s Scientific Advisory Board since its inception in 2018 Georg joined the company as Vice President of Drug Discovery in 2022. He has over 16 years of drug discovery experience with an emphasis on pharmacology, strategy, and innovation. Prior to joining DeepCure, Georg was an Associate Research Fellow at LEO Pharma where he worked for more than 13 years in a variety of positions at the company’s Danish headquarters and its Boston-based Science & Tech Hub where he served as Chief Scientist. Georg studied in Germany and the US and holds a PhD in Biochemical Pharmacology and MSc in Biology from the University of Konstanz. He also completed advanced executive education programs at the Wharton School of the University of Pennsylvania (CPD) and the MIT Sloan School of Management (ACE).

Han Lim Ph.D.

Chief Business Officer

Derrick Miyao

VP of Molecular Foundry


Elvira Haimov

Senior Scientist, Medicinal Chemistry

Elvira joined DeepCure in 2022 as a Senior Principal Scientist – Medicinal Chemistry. Previously, Elvira worked in TEVA, TAPI division, as a team leader, developing novel synthetic methodologies toward the synthesis of the Active Pharmaceutical Ingredient. Then, Elvira joined the Blavatnik Center for Drug discovery, pursuing medicinal chemistry and drug discovery. Elvira led medicinal chemistry through hit selections, hit validation, SAR studies, and hit-to-lead optimization.

Daniel Graziano

Biology Data Scientist

Danny is a biological data scientist who utilizes data-driven processes to re-imagine critical phases of the drug discovery life cycle. His primary interest is in making complex biological data relatable and accessible to a broad audience to draw conclusions and base decisions from. Danny brings 5+ years of in-vivo pharmacology experience from his time in the Novartis Neuroscience department. Throughout his work at Novartis and Massachusetts General Hospital, he developed skills in implementing DSP, time series, and statistical analysis pipelines for extracting translatable biomarker readouts from in-vivo electrophysiology data. He will be finishing his master’s degree in computer science from Boston University at the end of 2021.

Panos Terzopoulos

Machine Learning Engineer

With a diverse background in mechanical engineering and robotics, Panos completed his master thesis on computational biology in MIT and NTUA and he has been with DeepCure since then. He’s a machine learning scientist who works on finding practical solutions that bridges the gap between machine learning and the traditional drug discovery world.

Derek Miller

Director of Machine Learning

Derek Miller is a machine learning engineer with 9 years of experience and has worked in a variety of industries such as healthcare, genomics and drug discovery. His work focuses on training models at scale to help provide enriched molecules for a variety of different therapeutics.

Chris MacNaughton

Software Architect

Chris is a software architect with over 15 years of experience working in a broad spectrum of industries including education, e-commerce, pharma, precision health, and wellness. He works across the software stack to build large-scale, highly-available applications and platform services. He resides in Indianapolis, IN with his wife and 3 kids.

Michal Segal Salto Ph.D.

Associate Research Fellow, Biology

Michal joined DeepCure drug discovery team in 2022 as Associated research fellow. Michal has over 17 years of experience in cell biology, molecular biology and biochemistry. She was awarded her PhD from the Weizmann Institute of Science in Rehovot, Israel. In the past 7 years Michal led research groups and development processes in preclinical and clinical stages. Michal has in-depth understanding of applicable research, target and product identification and selection, as well as, experience in designing product development programs. Michal has published peer-reviewed articles in high impact factor journals and precipitated in many international conferences.

Mark Schroering

Associate Director, Lead Architect

Mark is a software architect with over 20 years of experience working for companies like Boeing, Raytheon, and Genesys. He has spent the last nine years building large-scale cloud platforms that have been deployed globally in the cloud and used by millions of people. His work has been used in the avionics, medical research, and contact center industries. Mark lives in Indianapolis, IN with his wife and two daughters.

Kelvin Chan Ph.D.

Director of DMPK

Kelvin joined DeepCure in 2022 as Director of Drug Metabolism and Pharmacokinetics (DMPK). He has broad experience and expertise in analytical chemistry, DMPK, and CMC (Chemistry, Manufacturing, and Control) areas. Since 1984, Kelvin’s career spanned large multinational (Syntex/Roche, Wyeth/Pfizer, Aventis/Sanofi, Alcon/Novartis), small biotech (Assembly Biosciences), and non-profit (CHDI) organizations. He had contributed to the discovery or development of multiple molecular entities to successful NDAs. Kelvin received his PhD in Chemistry from the University of Illinois and post-doctoral training at Cornell University.

Jason Deckman

Senior Scientific Software Engineer

Jason joined DeepCure in 2022 as a Senior Scientific Software Engineer. Jason has a Ph.D. in theoretical/computational chemistry from U.C. Irvine, and has several years of graduate and postdoctoral experience in scientific and numerical computing, applied to biochemical simulations and algorithm development. In industry before graduate school, Jason worked in the drug discovery arena, first as a chemist and as a data analyst, enumerating and curating virtual combinatorial chemistry libraries. In the last several years he has worked as a senior software engineer specializing in back-end infrastructure and cloud architecture, as well as full stack development. Jason is eager to combine his chemistry knowledge and software engineering experience to deliver novel and effective software solutions for DeepCure.

Ayelet Wagner Azran

Director of People Operations

With a passion for building strong cultural foundations, and identifying people’s needs for creating a successful work environment, Ayelet joined DeepCure as People Operations Lead in 2020. Previously, she had worked at several non-profit organizations and led the HR and operations of ELAL Israel airlines in Boston. She holds a Law degree and a Bachelors in business administration.

George Bikos

Senior Software Engineer

I am a Software Engineer with 3 Years of Experience. I have a Master’s in Computer Science and Informatics from the University of Patras, Greece. I started working as a Bioinformatics Researcher at the National Research Center of Greece and later jumped into the Health Industry, joining a company associated with Medical-Imaging. I am interested in the BioInformatics and Medical aspect of Engineering. I have lived in Athens, Greece for the last 3 years.

Patrick O’Neill Ph.D.

Senior Machine Learning Scientist

Patrick is a computational scientist with five years of industrial experience as a machine learning engineer. His professional interests include statistical sampling algorithms, transcriptional regulation, and applications of statistical physics to multiscale modeling problems. He received his Ph.D. in Biological Sciences from UMBC in 2016.

Pegah Kolahi

Scientist, Computational Chemistry

Pegah is a Computational Scientist with a broad in-silico expertise and background in computer-aided drug design and discovery. She graduated with her Masters from New York University in 2019 and has been working in the pharmaceutical and biotechnology industry since then. Throughout her work at Kadmon and Sanofi, she developed skills in advanced computational techniques such as molecular modeling, virtual library design and molecular dynamics to support designing and optimizing drug candidates. She is passionate about applying state-of-the-art computational chemistry tools to accelerate the discovery and design of therapeutics and determine novel paths forward for drug development.

Yair Cohen Ph.D.

Scientist, Synthetic Organic Chemistry

Yair joined DeepCure in 2022 as Scientist of Synthetic Organic Chemistry. Prior to joining DeepCure, Yair completed his Ph.D. in Organic Chemistry at the Technion, Israel, under the supervision of Prof. Ilan Marek. He believes in the power of organic chemistry to make impactful contributions to every scientific, engineering or technical project.

Sarah Bowes

Senior Executive Assistant

Sarah is an executive assistant and office manager at DeepCure. Before joining DeepCure, she attended Fairfield University with a Bachelor of Science in Marketing and Data Analytics.

William Kaplan

Principal Scientist, Medicinal Chemistry

Will joined DeepCure in 2022 as a Principal Scientist – Medicinal Chemistry. Previously, Will spent 4.5 years at Merck where he developed his skills in preclinical drug discovery spanning lead ID, lead optimization, design and synthesis, and program strategy/development. Will received his PhD in Medicinal Chemistry from the University of Michigan (Go Blue!).

Alex Vig

Senior Machine Learning Scientist

Alex took a curiosity driven deep dive into machine learning in 2013 and hasn’t looked back. He is especially interested in bringing to bear machine learning techniques from seemingly disparate fields to the challenges of drug development. In his free time, Alex enjoys woodworking, kiteboarding, and puzzling.

Zack Strater Ph.D.

Senior Scientist, Machine Learning

Zack is a synthetic chemist and machine learning scientist whose primary interest lies in combining machine learning methods with high-throughput experimentation in chemical synthesis. He did his Ph.D. work at Columbia University where he developed the merger of photo- and electrocatalysis and subsequently co-founded XL Batteries, a startup flow battery company where he designed novel organic electrolytes.

Ohad Hasin Ph.D

Laboratory Administrator

Ohad joined Deepcure in 2022 as a laboratory administrator. Ohad holds a Ph.D degree in organic chemistry and marine biology from Tel-Aviv university, since then worked in lab managing and team lead positions prior his arrival to Deepcure.

Cheryl Koh Ph.D.

Associate Director Biology

Cheryl is a cancer biologist with over ten years of academic and industry research experience. Cheryl received her Ph.D. in Pathobiology from the Johns Hopkins University School of Medicine and completed her post-doctoral fellowship at the Institute of Molecular and Cell Biology, A*STAR. Cheryl developed broad early drug discovery experience, encompassing various therapeutic areas (Oncology, Immuno-oncology and Neuroscience) and target classes, during her time at AstraZeneca and Silicon Therapeutics (Roivant Discovery). Cheryl was part of the cross-functional pre-clinical discovery team that delivered Silicon Therapeutics’ first clinical candidate. Cheryl has published 20 peer-reviewed articles in various high-impact journals, including a co-first author publication in Nature.

Geetha Venkateswaran Ph.D.

Scientist, Biology

Geetha joined DeepCure in 2022 as a Scientist, Biology. Geetha has a Ph.D. in Oncology from the University of British Columbia. She has experience in the design and implementation of studies for cancer biology projects and has contributed to research work published in high impact factor, peer reviewed journals.

Alex Bernstein

Robotics and Automation Engineer

Alex is an electronics engineer with more than 15 years of experience working for medical and analytical devices companies, life science startups, oncology institutes and pharmacology companies like “Teva” and “Jonhson & Johnson”. Alex joined DeepCure in 2022 and serves as our robotics and automation specialist at the Molecular Foundry dept. M.Sc. Engineer at the office, jazz trumpet player out of the office. Holds belts in karate and aikido, winner of 2010 Israel Goju Ryu Karate Cup. Lives in Rehovot, Israel with his wife, daughter and 3 dogs. His dream is to make the world healthier and happier.

Jacob Gillis

Senior Scientific Program Manager

Jacob is a project and program manager with over 5 years of scientific program management and product development experience with start-up assay development companies, working to expand and refine product development programs and implement quality management processes. Jacob joins DeepCure with a focus on scientific program optimization and maximizing program efficiency.

Steven Ferrara, Ph.D

Director of Medicinal Chemistry

Steven joined DeepCure in 2021 and serves as our Associate Director of Medicinal Chemistry. He has over eight years of drug discovery experience with an emphasis on medicinal chemistry and chemical biology. Prior to joining DeepCure, Steven was a Group Leader at the Broad Institute of MIT and Harvard, where he led a group of medicinal chemists who focused on developing novel therapeutic strategies for use in oncology and cardiovascular disease areas. He played an important role in advancing several preclinical programs and was a key contributor and co-inventor of inhibitors targeting DHODH (BAY 2402234) and MCL1 (ANJ810). Steven received his Ph.D. in Organic Chemistry from the University of Oxford and was a postdoctoral research associate at Yale University. He also holds a Master of Chemistry from the University of Sheffield.

Board of Directors

Kfir Schreiber

CEO & Co-Founder

Graduate of the MIT Media Lab. Recipient of the inaugural Minsky Fellowship for prominent AI researchers. Previously a Pilot and Major in the Israeli Air Force, with a track record of managing over $100M and 20 people across major R&D projects.

Joseph Jacobson, Ph.D.

CSO & Co-Founder

Associate Professor at the MIT Media Lab. Author of over 70 peer-reviewed papers and conference proceedings. Inventor of 103 issued U.S. patents and a member of the USPTO Investors Hall of Fame. Co-Founder of several successful companies including E-Ink, Gen9, Kovio and IgC Bio.

Gerald Chan


Gerald Chan is the co-founder of Morningside, an investment group engaged in private equity and venture capital investments. Working with academic scientists, he has started more than two dozen biotech companies across diverse therapeutic areas of oncology, inflammation, ophthalmology, autoimmunity, diabetes, neurodegeneration, rare genetic diseases, and prophylactic vaccines. Gerald is a board member of several privately held biotech companies. He is the chairman of two Nasdaq listed biotechnology companies: Apellis Pharmaceuticals and Stealth BioTherapeutics. From 2016 to 2020, he chaired the Innovation Advisory Committee of the Wellcome Trust. He is currently a trustee of the Scripps Research Institute and a member of the Dean’s Board of Advisors of the Harvard T.H. Chan School of Public Health, which was renamed in honor of his father, Mr. T.H. Chan, following a gift from the Morningside Foundation in 2014. Gerald was educated at UCLA, Harvard University, and Dana Farber Cancer Institute. He has been honored with six honorary degrees conferred by universities in the UK, Hong Kong and America. In 2017, he was elected to membership in the American Academy of Arts and Sciences. In 2019, he gave the Andrew Carnegie Lecture in University of Glasgow, Scotland and held a visiting fellowship at Trinity College, Cambridge University.

Yonatan Mandelbaum


Investing principal at TLV Partners. At the firm since 2017, he spends most of his time on fintech, bottoms-up SaaS and anything out of the ordinary, but has a true passion for working closely with humble founders whose ambitions vastly outweigh their accomplishments. Prior to joining TLVP, Yonatan was an analyst at iAngels. He holds a bachelors in finance from IDC Hertziliya, spent two years studying at Yeshivat Har Etzion and served as a commander in the Israeli Defense Force’s Haruv unit.

Shahar Tzafrir


Managing Partner at TLV Partners where he focuses on seed-stage investments at the intersection of AI, enterprise, and bio. Shahar began his venture career at Magma Venture Partners as a General Partner in funds III and IV. While at Magma, Shahar led seed investments in Aidoc, Guesty, Applitools (acquired by Thoma Bravo), Argus (acquired by Continental), Cloudendure (acquired by Amazon), and Indegy (acquired by Tenable), among others. Before venture capital, Shahar spent 17 years across three enterprise software startups: Federation (acquired by Cordys), Oblicore (acquired by CA) and DigitalFuel (acquired by VMware). Prior to that, Shahar spent six years in the Israeli Defense Force’s Mamram computer division as a software developer, where he received three annual distinction awards.

Thrasyvoulos (Thras) Karydis


Graduate of the MIT Media Lab. Deep Learning and AI expert, with years of experience in leading hardware and software projects. Vast experience in establishing and leading collaborations with large pharma companies.

Scientific Advisory Board

John Baldoni, Ph.D

Ex SVP, DPU Head, In-Silico Discovery, GSK Pharmaceuticals

Headed innovative drug discovery unit dedicated to explore and apply in silico methodology to drug discovery and development at GSK. This followed his role as Senior Vice President, Platform Technology and Science (PTS), GSK Pharma R&D. Joined GSK in 1989 and worked in the pharmaceutical industry for 42 years. His experience spans new chemical entity design, development and commercialization, and biopharmaceutical development. Held various positions at GSK including Senior Vice President, Preclinical Development; Vice President, Product Development; Director, Product Development; and Assistant Director, Biopharmaceutical Formulation Development, among others. Led several key cross-functional problem solving and strategic initiatives. BS in biochemistry (1974), and MS and Ph.D. degrees in chemistry (1980) from Penn State University.

Marti Head, Ph.D

Director Joint Institute, Oak Ridge National Laboratory

Director of the Joint Institute for Biological Sciences, a collaborative research effort between Oak Ridge National Laboratory and the University of Tennessee focused on new approaches to drug development, personalized treatment, diagnosis and prediction of outcomes in health management.